31 completed, 7 recruiting, 5 unknown, 4 active not recruiting. 18 Phase 2, 8 Not applicable, 8 Phase 3, 2 Phase 1, 1 Phase 4.
Follow Autosomal Dominant Polycystic Kidney Disease: new trials by email Literature Review of Autosomal Dominant Polycystic Kidney Disease trials Research Report on Autosomal Dominant Polycystic Kidney Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Managing Depressive Symptoms in ADPKD Mayo Clinic-Approved Education, Digital Neuropathy, Capacity Coaching - Autosomal Dominant Polycystic Kidney Disease | Not applicable | Recruiting | Mayo Clinic | 105 | 2026-06-12 | 2026-08-07 |
| Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease AZD1613 - Part A, Placebo - Part A, AZD1613 - Part B - Autosomal Dominant Polycystic Kidney Disease | Phase 1 | Recruiting | AstraZeneca | 40 | 2025-11-10 | 2026-10-13 |
| ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) ABBV-CLS-628, Placebo - Autosomal Dominant Polycystic Kidney Disease | Phase 2 | Recruiting | Calico Life Sciences LLC | 240 | 2025-06-09 | 2026-10-06 |
| Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease Empagliflozin, Placebo - Autosomal Dominant Polycystic Kidney Disease | Phase 2 | Completed | Cantonal Hospital Graubuenden | 16 | 2024-09-01 | 2026-09-22 |
| Role of ROS and cAMP-PKA Biomarkers in ADPKD Autosomal Dominant Polycystic Kidney Disease | Active not recruiting | Mayo Clinic | 100 | 2023-07-01 | 2025-10-27 | |
| Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease Atorvastatin 20 Mg Oral Tablet, Sodium Bicarbonate 600 Mg Oral Tablet - Autosomal Dominant Polycystic Kidney Disease, Chronic Kidney Diseases | Phase 2 | Enrolling by invitation | Taipei Medical University Shuang Ho Hospital | 30 | 2023-05-01 | 2023-05-23 |
| Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD) Metformin XR, Control - Autosomal Dominant Polycystic Kidney Disease | Phase 3 | Recruiting | The University of Queensland | 1174 | 2022-11-29 | 2026-03-31 |
| A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease RGLS8429, Placebo - Autosomal Dominant Polycystic Kidney Disease, ADPKD | Phase 1 | Completed | Regulus Therapeutics Inc. | 68 | 2022-10-06 | 2025-06-03 |
| Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration PB - Autosomal Dominant Polycystic Kidney Disease, Nephrogenic Diabetes Insipidus | Phase 2 | Completed | Mayo Clinic | 36 | 2022-09-01 | 2026-01-27 |
| Renal Denervation in ADPKD- RDN-ADPKD Study Renal denervation - Uncontrolled Hypertension, Autosomal Dominant Polycystic Kidney Disease | Not applicable | Active not recruiting | University of Erlangen-Nürnberg Medical School | 44 | 2022-06-14 | 2026-05-05 |
| Intrarenal Microvasculature in ADPKD Autosomal Dominant Polycystic Kidney Disease | Active not recruiting | Mayo Clinic | 34 | 2021-11-30 | 2026-01-16 | |
| A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD Autosomal Dominant Polycystic Kidney Disease | Active not recruiting | Mayo Clinic | 80 | 2021-09-14 | 2026-04-16 | |
| A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) GLPG2737, Placebo - Autosomal Dominant Polycystic Kidney Disease | Phase 2 | Terminated | Lakefront Biotherapeutics NV | 66 | 2020-11-10 | 2024-08-22 |
| NOX4 and Related Biomarkers in ADPKD Autosomal Dominant Polycystic Kidney Disease | Recruiting | Mayo Clinic | 60 | 2020-07-21 | 2026-01-09 | |
| Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) Autosomal Dominant Polycystic Kidney Disease | Recruiting | Mayo Clinic | 40 | 2019-10-04 | 2026-01-16 | |
| Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease Pravastatin, sodium citrate - Autosomal Dominant Polycystic Kidney Disease | Phase 2 | Completed | University of Southern California | 1 | 2019-01-30 | 2025-08-06 |
| Tolvaptan-Octreotide LAR Combination in ADPKD Tolvaptan, Octreotide LAR, Placebo - Autosomal Dominant Polycystic Kidney Disease | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 20 | 2018-12-12 | 2022-11-03 |
| ADPKD Alterations in Hepatic Transporter Function ADPKD, Autosomal Dominant Polycystic Kidney Disease | Completed | University of North Carolina, Chapel Hill | 24 | 2018-09-17 | 2020-03-25 | |
| The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease Lixivaptan - Autosomal Dominant Polycystic Kidney Disease | Phase 2 | Completed | Palladio Biosciences | 31 | 2018-09-14 | 2022-12-05 |
| Autosomal Dominant Polycystic Kidney Disease Somatic Mutation Biorepository Autosomal Dominant Polycystic Kidney Disease | Enrolling by invitation | Weill Medical College of Cornell University | 100 | 2018-06-01 | 2026-01-22 |
Showing 20 of 53. Sign in to see all of them.
Polycystic Kidney, Autosomal Dominant (53) · Polycystic Kidney Diseases (7) · Kidney Diseases (5) · Diabetes Insipidus (3) · Diabetes Insipidus, Nephrogenic (2) · Disease Progression (2) · Renal Insufficiency, Chronic (2) · Adenine phosphoribosyltransferase deficiency (1) · Atypical Hemolytic Uremic Syndrome (1) · Bartter Syndrome (1) · Calciphylaxis (1) · Cystinosis (1) · Cystinuria (1) · Cysts (1) · Dent Disease (1)
Abnormalities, Multiple (53) · Ciliopathies (53) · Congenital Abnormalities (53) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (53) · Female Urogenital Diseases (53) · Female Urogenital Diseases and Pregnancy Complications (53) · Genetic Diseases, Inborn (53) · Kidney Diseases, Cystic (53) · Male Urogenital Diseases (53) · Urogenital Diseases (53) · Urologic Diseases (53) · Kidney Diseases (48) · Polycystic Kidney Diseases (46) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7)
Tolvaptan (9) · Everolimus (2) · Antihypertensive Agents (1) · Atorvastatin (1) · Cosyntropin (1) · Pravastatin (1) · Saline Solution (1) · Sirolimus (1) · Sodium Bicarbonate (1) · Sodium Chloride (1) · Sodium Citrate (1) · Tablets (1) · adrenocorticotropin zinc (1) · empagliflozin (1) · lixivaptan (1)
Mayo Clinic (10) · Otsuka Pharmaceutical Development & Commercialization, Inc. (4) · Kyorin University (3) · Federico II University (2) · Mario Negri Institute for Pharmacological Research (2) · Otsuka Pharmaceutical Co., Ltd. (2) · University of Kansas (2) · Andreas L. Serra (1) · Assistance Publique - Hôpitaux de Paris (1) · AstraZeneca (1) · CHU de Reims (1) · Calico Life Sciences LLC (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Cantonal Hospital Graubuenden (1) · Emory University (1)
United States (26) · France (8) · Germany (7) · United Kingdom (7) · Italy (6) · Japan (6) · Belgium (5) · Netherlands (5) · Spain (5) · Australia (3) · Czechia (3) · Switzerland (3) · Austria (2) · Canada (2) · China (2)
Eiji Higashihara, MD (2) · Frank Czerwiec, M.D., Ph.D. (2) · Maria V Irazabal, M.D., Ph.D. (2) · Andreas L Serra, MD (1) · Andrew Mallett, MBBS, PhD (1) · Arlene Chapman, MD (1) · Bora Uslu, Fellow (1) · Changlin Mei, MD (1) · Connie Wang, MD (1) · Debra Sullivan, PhD, RD (1) · Eiji Higashihara, M.D. (1) · Erling B Pedersen (1) · Fatih Tufan, Fellow (1) · Fouad Chebib, MD (1)
PMID 39356039, PMID 41385299, PMID 37250503, PMID 41348481, PMID 20581392, PMID 20876670, PMID 21903984, PMID 23520042, PMID 24374109, PMID 24489795, PMID 26718059, PMID 26811129, PMID 26844873, PMID 27537328, PMID 28810844, PMID 28983800, PMID 29105594, PMID 29743334, PMID 30230107, PMID 30951521, PMID 31014270, PMID 32709218, PMID 32843370, PMID 36191725, PMID 36754009, PMID 37986188, PMID 38837240, PMID 39331470, PMID 40855441, PMID 41643210, PMID 41701531
2014 (1), 2017 (1), 2019 (1), R01DK128017 (1), R21DK118391 (1), R21DK129886 (1), R35GM122576 (1)